Latest Ophthalmology News

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Nova Eye Medical has gained regulatory approval for its iTrack Advance glaucoma device in China, setting the stage for significant market expansion and sales growth from late fiscal 2026.

PYC Therapeutics has restructured its Board and executive team to steer the company through pivotal clinical milestones expected by the end of 2027. The changes signal a strategic push toward late-stage development of its RNA-based drug candidates.

Cambium Bio has secured a strategic partnership with French pharmaceutical leader Benta SAS to commercialise its regenerative dry eye treatment, Elate Ocular, across Europe and the Middle East. This follows a second platelet-lysate licensing deal within days, underscoring growing industry confidence in Cambium’s platform.

PYC Therapeutics has completed dosing in its Phase 1 study of PYC-001 for Autosomal Dominant Optic Atrophy, showing strong safety and early signs of improved vision. The company plans to launch a global Phase 1/2 trial later this year.

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

Cambium Bio reported a $3.84 million loss for FY25 but secured critical FDA approvals and ethics clearances to initiate Phase 3 trials of Elate Ocular®, supported by a $2.12 million capital raise.

Cambium Bio has updated its placement, raising A$2.17 million to fund late-stage clinical trials for its lead ophthalmology product, Elate Ocular®. The capital raise reflects strong investor interest and strategic backing.

Cambium Bio has raised A$2.12 million through a fully subscribed placement led by Taiwanese institutional investor Da Jyun Capital, supporting the initiation of pivotal Phase 3 trials for its lead ophthalmology candidate.

Nova Eye Medical has reported a record A$29.2 million revenue for FY25, driven by strong sales growth and improved profitability in its glaucoma segment. The company targets breakeven EBITDA in the first half of FY26 alongside continued cash flow improvements.

Cambium Bio has secured FDA clearance to begin Phase 3 dosing of Elate Ocular, a promising treatment for moderate to severe dry eye disease, pending additional financing.

Nova Eye Medical has reported a record A$28.8 million in revenues for FY25, driven by strong US sales and sustained growth of its flagship iTrack™ Advance device.